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Abstract
Cancer cells possess traits reminiscent of those ascribed to normal stem cells. It is unclear,
however, whether these phenotypic similarities reflect the activity of common molecular
pathways. Here we analyze the enrichment patterns of gene sets associated with embryonic stem
(ES) cell identity in the expression profiles of various human tumor types. Strikingly,
histologically poorly differentiated tumors display preferential overexpression of genes normally
enriched in ES cells, combined with underexpression of Polycomb-regulated genes. Moreover,
expression of activation targets of Nanog, Oct4, Sox2 and c-Myc is observed more frequently in
poorly differentiated tumors than in well-differentiated tumors. In breast cancers this ES-like
signature is associated with high-grade ER-negative tumors, often of the basal-like subtype, and
with poor clinical outcome. The ES signature is also present in poorly differentiated glioblastomas
and bladder carcinomas. We identify a subset of ES-associated transcription regulators that are
preferentially expressed in poorly differentiated tumors. Our results reveal a novel link between
genes associated with ES cell identity and the histopathological traits of tumors, and support the
possibility that these genes contribute to stem cell-like phenotypes displayed by many tumors.
Introduction
The apparent parallels between tumor cells and normal stem cells have generated great
interest in the possible links between these two classes of cells. The hallmark traits of stem
cells – self-renewal and differentiation capacity – are mirrored by the high proliferative
capacity and phenotypic plasticity of tumor cells1. Moreover, tumor cells often lack the
terminal differentiation traits possessed by their normal counterparts. These parallels have
given rise to the hypothesis that tumors often arise from undifferentiated stem/progenitor
cells, or alternatively, that cancer cells can undergo progressive de-differentiation during
their development1-3. Additionally, some have proposed that cancer stem cells – a
subpopulation of cancer cells possessing tumor-initiating capability – are derived from
normal stem cells1,4. While certain regulators of stem cell function have been implicated in
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cancer pathogenesis2, a broad description of the activity of stem cell-associated regulatory
networks in tumors is lacking.
The differentiation level (or grade) of human tumors is assessed routinely in the clinic,
poorly differentiated tumors generally exhibiting the worst prognoses. However, this
classification is based on histopathological criteria, and the underlying molecular pathways
controlling tumor differentiation are poorly described. Moreover, it is not known whether a
lack of histological differentiation markers in tumor cells reflects the possession of stem
cell-like traits. A number of oncogenes are known to interfere with normal cell
differentiation, myc being a notable example5,6, and such oncogenes could also affect tumor
cell differentiation. The recent demonstration that adult fibroblasts can be reprogrammed
into pluripotent ES-like cells7,8 raises the possibility that the combined expression of stem
cell-associated factors and specific oncogenes could also induce a non-differentiated state in
cancer cells. In fact, ectopic expression of Oct4, a central determinant of ES cell identity, is
sufficient to induce tumor growth in the adult mouse9, and Polycomb complex components
central to stem cell function, such as Bmi1 and Ezh2, are also oncogenic10.
These observations suggest that the regulatory networks controlling the function of stem
cells may also be active in certain tumors. These networks have been the focus of much
recent interest, and progress has been made particularly in the study of ES cells11. Current
evidence indicates that some of the key regulators of ES cell identity – Oct4, Sox2 and
Nanog – are expressed only in specific human cancer types12-15. Nevertheless, it is
conceivable that different regulators – possibly paralogs of these ES cell factors – may
activate stem-cell regulatory networks in other tumor types. By necessity, detection of the
activity of such complex networks must rely on expression analysis of many genes in
multiple cancer samples, rather than on the presence or absence of individual factors16,17.
Here, we employed recently developed gene set expression analysis methods18 to assess
whether the expression signatures and regulatory networks that define human ES cell
identity are also active in human tumors. Our results reveal previously undescribed links
between tumor pathogenesis and the ES cell state.
Results
Gene sets reflecting ES cell identity
We wished to examine whether the regulatory networks that function in ES cells are also
active in tumors. Since different subsets of the many genes involved in these networks may
be active in different individual tumors, we reasoned that expression analyses of gene sets
(groups of genes related through a common function, pathway or other property) could
prove more revealing than single-gene analyses16,17,19. Accordingly, we set out to collect
gene sets that represent the core expression signature of ES cells and reflect the activity of
the regulatory pathways associated with their identity. We extracted these sets directly from
published studies without modifying their contents. In order to eliminate effects of inter-
species differences20,21, we used only gene sets identified in human cells.
We compiled 13 partially overlapping gene sets, which fall into four groups (Table 1,
Supplementary Table 1): (i) ES expressed genes: two sets of genes overexpressed in ES
cells compared to other cells and tissues according to a multi-study compilation and meta-
analysis22. (ii) Nanog, Oct4 and Sox2 (NOS) targets: four sets of genes whose promoters
are bound and activated in human ES cells by each of these regulators of ES cell identity, or
co-activated by all three23, and an additional set (NOS TFs) including a subset of NOS
activation targets encoding transcription regulators. (iii) Polycomb targets: four sets
representing genes bound by the Polycomb Repressive Complex 2 (PRC2) in human ES
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cells24. (iv) Myc targets: two sets of genes bound and activated by c-Myc, identified in two
independent studies25,26. We hypothesized that these 13 gene sets would allow the
definition of an ES-cell expression signature and, in turn, the detection of this signature in
tumors.
Establishment of an ES cell gene-set enrichment pattern
We employed a recently described computational strategy to assess the expression pattern of
the above gene sets in microarray expression data18. This method tests whether the genes
that are over- or underexpressed in each profiled tissue or cell line include a higher-than-
randomly-expected fraction of genes from a particular gene set (Fig. 1a). A second analysis
step determines whether particular sample groups (e.g., all ES cell samples) preferentially
under- or overexpress particular gene sets (Fig. 1a).
We first analyzed the enrichment patterns of the 13 gene sets in an expression profile dataset
that included 5 human ES lines, 7 embryonic carcinoma (EC) lines, and various other
normal and tumorigenic cells and tissues27. This analysis revealed that the various ES-
expressed and NOS-target gene sets were, as anticipated, preferentially overexpressed in the
ES and EC samples, while the Polycomb-target sets were underexpressed in these samples
(Fig. 1b). The highest levels of gene set enrichment were observed for the ES exp1 set (P
values ranging from P =10-28 to 10-53 in individual ES lines), which includes 380 genes
shown to be overexpressed in ES cells in 5 profiling studies or more22. Myc-target gene sets
showed lower enrichment levels in the ES lines. Interestingly, normal testis samples and
normal cultured cells displayed an enrichment pattern opposite to that of ES cells, while the
various tumor cell lines did not display a consistent gene set enrichment pattern (Fig. 1b).
These findings were also evident in the sample-group analysis (Fig. 1c). The NOS TFs set
was the only set enriched in the male germ-cell tumor group (Fig. 1b,c), despite the fact that
only half of the genes in this small set were included in the arrays used in this study27. This
interesting finding corresponds to the known activity of ES cell-associated transcription
regulators in germ-cell tumors12,13.
These analyses indicated that the combined enrichment pattern of the 13 gene sets can be
viewed as a gene-set based expression signature, and that a specific enrichment pattern/
signature associated with ES cell identity can be defined.
Poorly differentiated breast tumors display an ES-like expression signature
We proceeded to test whether the ES-associated gene sets were enriched in human tumors.
We generated a compendium of data from six published studies of breast cancer expression
profiles28-33 comprising a total of 1,211 tumors. Available tumor annotations were derived
from the original publications, and included tumor grade, size, estrogen receptor (ER)
expression, metastasis to lymph nodes or to distant organs, and disease-associated mortality.
Strikingly, analysis of the enrichment patterns of the 13 gene sets across the compendium
samples revealed that poorly differentiated (grade 3) breast tumors display an enrichment
pattern resembling that observed in ES cells. This included underexpression of Polycomb
target gene sets and overexpression of ES-expressed sets, Myc-target gene sets, and some of
the NOS-target gene sets (Fig. 2a,b). Conversely, the well-differentiated, grade 1 tumors
displayed an opposite pattern. The most significant enrichment levels were observed for the
ES-expressed and Polycomb-target sets (P=10-13 to P=10-50 for sample group enrichments
in grade 3 tumors, Fig 2b). Interestingly, the NOS TFs gene set was among those enriched in
high-grade breast cancers (P =6.3×10-5). We observed this overall enrichment pattern with
limited variation when analyzing the individual studies comprising the compendium
separately (data not shown).
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These findings revealed that tumors that are defined as poorly differentiated according to
purely histopathological criteria, in fact display a molecular similarity to ES cells, as
reflected by the coordinated up- or down-regulation of gene sets associated with ES cell
identity. This similarity suggests that the neoplastic cells within such tumors are closer in
their traits to normal undifferentiated stem cells than are cells in well-differentiated tumors.
Association of the ES signature with ER-status, tumor size, and intrinsic subtype
We examined whether enrichments of the 13 gene sets would be observed when the breast
tumors in our compendium were stratified according to criteria other than tumor grade. Our
analysis indicated that tumors lacking expression of the estrogen receptor (ER-negative)
displayed an ES-like enrichment pattern when compared to the receptor-expressing (ER-
positive) tumors (Fig. 2a, 3a). Most ER-negative tumors are poorly differentiated, indicating
an overlap between these two categories. We therefore analyzed gene-set enrichments in the
tumors stratified into six groups representing all possible combinations of these two
parameters (Figure 3b). This analysis indicated that, even within the same ER status, high-
grade tumors were more ES-like in their enrichment pattern than were low-grade tumors;
similarly, ER-negative tumors within the same grade were more ES-like than their ER-
positive counterparts (Figure 3b). The ES signature is thus independently associated with
both tumor grade and ER status, with grade 3/ER-negative tumors showing the overall most
significant gene-set enrichments. Subtraction of genes closely associated with ER-status did
not significantly affect this enrichment pattern (Supplementary Figure 2c).
Interestingly, tumors of larger size at the time of diagnosis (more than 2 cm diameter) were
also more likely to possess the ES signature compared to smaller tumors, even within a
given grade (Fig. 3a,b). These results could suggest that tumors de-differentiate as they
grow; alternatively, it is possible that poorly differentiated tumors are initially detected at
larger sizes due to their enhanced growth rates.
Perou and colleagues have defined five “intrinsic subtypes” of breast cancer on the basis of
tumor expression profiles: normal-like, luminal type A, luminal type B, HER2-like, and
basal-like34,35. We classified the tumors in our compendium using this method and then
tested whether the 13 gene sets displayed enrichments in particular subtypes. Strikingly, the
basal-like tumors showed an ES-like signature with highly significant gene set enrichments
(Fig. 3a), while at the other extreme, luminal type A tumors displayed the opposite pattern.
Basal-like tumors are mostly grade 3 and ER-negative, possessing a high proliferation rate
and a high nucleus-to-cytoplasm volume ratio36,37. Recent histological analysis revealed
that these tumors often express markers of both the luminal and the myoepithelial/basal
lineages present in the normal mammary duct37, suggesting that they arise from a still-
unidentified, mammary stem/progenitor cell3. The association between the basal-like
subtype and the ES signature suggests that, when compared with other breast cancer
subtypes, these basaloid tumors may possess traits rendering them more similar to normal
stem cells.
The ES signature is associated with poor prognosis
Analysis of gene-set enrichments in the breast tumors stratified according to clinical
progression parameters (lymph node and distant metastasis, overall survival) revealed only
weak associations of the ES-associated sets with poor outcome (Figure 3c). To assess
whether presence of the ES signature is associated with poor prognosis in a more detailed
manner, we performed Kaplan-Meier analyses of overall survival for patients included in
five independent studies28,30,31,33,38. Tumors that displayed both overexpression of the ES
exp1 set and underexpression of the PRC2 targets set were labeled as possessing the ES
signature for this purpose. Patients carrying this signature displayed worse survival than the
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remaining patients, with significance levels varying from study to study (Figure 3d). A
meta-analysis of survival data from the five studies together indicated that the mortality rate
of patients carrying the ES signature was significantly higher (p<0.0001), with a hazard ratio
of 2.03 (Supplementary Fig. 1). This analysis also indicated that the ES signature provides
prognostic information beyond that provided by tumor grade, and is predictive of poor
outcome even when patients of the basal-subtype are excluded. Thus, possession of the ES
signature is indicative of aggressive tumor behavior in vivo.
The ES signature is not a direct reflection of proliferation rates
Breast cancer grade is determined using metrics for duct formation, nuclear atypia, and
mitotic index; poorly differentiated tumors therefore often contain more proliferating cells
than do well-differentiated tumors. Since ES cells are characterized by a high proliferation
rate39, we wished to assess the contribution of proliferation-related genes to the observed
gene set enrichments. We collected three different sets of proliferation genes
(Supplementary Table 3): genes functionally involved in proliferation (based on Gene
Ontology (GO)), genes displaying cell-cycle stage-specific expression40, and genes
belonging to a “Proliferation Cluster” defined in human breast tumor expression data35. We
first examined the enrichment pattern of these sets in ES cells relative to other cell types.
Interestingly, the proliferation-associated sets were overexpressed in ES and EC samples,
and, also, in most cultured tumor cell lines (Fig. 4a). This enrichment pattern contrasted with
that displayed by the ES gene sets, which were not overexpressed in the tumor cell lines
despite the rapid proliferation of the latter (Fig. 4a). This finding indicates that the ES gene
sets specifically reflect an ES-like phenotype, rather than a general state of rapid
proliferation
Next, we generated three amended versions of our original gene sets, from which genes
included in each of the proliferation sets were removed. Analysis of the enrichment patterns
of the modified gene sets revealed that most of the sets still displayed highly significant
enrichments (Fig. 4b, Supplementary Fig. 2a,b), indicating that the ES signature can be
detected in high grade, ER-negative and basal tumors even without the influence of
proliferation-associated genes. However, for some gene sets, including the Nanog targets,
Oct4 targets and Sox2 targets, the association with tumor grade was dependent to a greater
extent on the inclusion of proliferation genes (Fig. 4b, Supplementary Fig. 2a,b).
Lastly, we extracted subsets of genes from the ES exp1 gene set, each associated with a
specific cellular function, according to GO annotations (Fig. 4c). Strikingly, in addition to
the Cell Cycle subset, all other functional subsets tested were significantly overexpressed in
high-grade cancers as well (Fig. 4c). These combined results indicate that while
proliferation-related genes are an inherent part of the ES signature, many other genes,
involved in a variety of other, distinct cellular functions, also contribute to this signature and
to its enrichment in specific tumors.
The ES signature appears in poorly differentiated cancers of various types
We examined whether the ES signature was present in tumors arising in tissues other than
the breast. Analysis of the expression profiles of 157 gliomas41 revealed a striking
correlation between tumor grade and the presence of the ES-like signature (Fig. 5a): grade 4
glioblastomas, which represent the most aggressive subtype of glioma, displayed significant
gene-set enrichments corresponding to the ES signature, while the other glioma types
included in this study (oligodendrogliomas and astrocytomas of grades 2 and 3) displayed
lower enrichment levels for this signature in a manner that correlated with their lower
grades. Normal brain tissue showed opposite enrichments (Fig. 5a), although a direct
comparison is difficult in this case, due to the sampling of multiple distinct cell types.
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We also analyzed an expression dataset of bladder carcinomas, which included normal
urinary tract samples as well as grade 2 and 3 transitional cell carcinomas42. Here, as well,
the high-grade tumors displayed an ES-like gene set enrichment pattern (Fig. 5b). Other
parameters, such as superficial vs. invasive, did not show a strong correlation with the
presence or absence of the ES signature (Fig. 5b). These results together indicate that an ES-
like signature is present in poorly differentiated cancers arising in various tissues from
distinct cells-of-origin.
The ES signature is not preferentially associated with the tumor-initiating fraction of
breast cancer cells
Cancer stem cells, a subfraction of neoplastic cells possessing tumor-initiating capability,
have recently been described in solid and hematopoietic tumors4. In breast cancers, a
CD44high/CD24low tumor-initiating population has been identified, and the expression
profiles of this population and of the non-tumor-initiating population (from 3 individual
tumors) have recently been reported43. Since cancer stem cells have been suggested to
possess stem cell-like traits3,4 we examined the behavior of the ES gene sets in these
samples. Interestingly, the ES signature was not consistently associated with either the
tumor-initiating or non-tumor-initiating population (Supplementary Fig. 3). This finding
does not support a notion by which the tumor-initiating cells provide a high contribution to
the ES signature observed in high-grade tumors. However, the small number of samples in
this study does not allow definitive conclusions. We noted, however, that the CD24 gene is
in fact highly expressed in ES cells22 and is also preferentially expressed in poorly-
differentiated, ER-negative breast tumors (Supplementary Fig. 4c).
A set of ES cell-associated transcription regulators is expressed in poorly differentiated
cancers
We hypothesized that among the genes expressed in ES cells, those encoding transcription
regulators could provide an important contribution to tumor phenotypes. To identify such
candidates, we extracted 68 genes encoding transcription regulators from the two ES Exp
sets and the NOS TFs set (Supplementary Table 4). Hierarchical clustering across our breast
cancer compendium revealed that a subset of 9 of these genes were preferentially and
coordinately overexpressed in the high grade, ER-negative tumors (Fig. 6a,b, Supplementary
Fig. 4a,b). Interestingly, several genes previously associated with adult stem/progenitor
function, with ES and tumor cell proliferation, and/or with cancer progression were included
in this “Core 9” subset. These included KLF5, which can replace KLF4 in somatic cell
reprogramming44, TCF7L1, the ortholog of mouse Tcf3, which plays a pivotal role in skin
stem cells45, and TEAD4, a co-factor of Yap1 in Hippo pathway signaling46.
Examination of the enrichment pattern of the Core 9 genes, when defined as a distinct gene
set, revealed that they are preferentially overexpressed not only in high grade, ER-negative
and basal-like breast cancers (Fig. 6c), but also in high-grade glioblastomas and bladder
carcinomas (Fig. 6d,e). These findings indicate that specific transcriptional regulators
normally active in ES cells are often overexpressed in poorly differentiated tumors arising in
distinct tissues. Notably, the known central regulators of ES identity – Nanog, Oct4 and
Sox2, as well as Stat3 and Lin28 – are not broadly expressed in high-grade breast cancers
(Supplementary Fig. 4a) and therefore are not included in the Core 9 set.
We next ranked all the genes encoding known and putative transcription regulators in the
human genome by the degree of correlation of their expression with that of the Core 9 genes
in the breast cancer compendium. The top ranked 100 genes (Supplementary Table 5) were
generally enriched in high-grade cancers (Fig. 6c-f). These highly correlated genes included
members of families encoding developmental regulators, such as Sox and Ets-domain
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proteins, as well as factors associated with proliferation, such as E2F1, c-Myc, and FoxM1.
Importantly, the Polycomb complex components Ezh2 and Eed were also included in this
list, indicating that high Polycomb activity goes hand-in-hand with expression of ES-
associated transcription factors, and providing a possible mechanism for the increased
repression of Polycomb targets observed in high-grade tumors. We suggest that the
combined activity of these regulators contributes to generating a poorly differentiated state
in tumors.
Discussion
The relationship between neoplastic cells and normal stem cells represents a question of
great current interest. Some have postulated that the pathways conferring self-renewal
capacity on normal stem cells may perform a similar function in cancer cells1. Examples of
such appropriation of specific stem cell-associated regulators and signaling pathways by
tumors have been described1,2. Here, we attempted to provide a broad view of the presence
of molecular imprints of stemness in cancer, by examining the activity of gene sets
associated with human ES cell identity in human tumors. Our analyses revealed an inverse
relationship between the presence of an ES-like gene set enrichment signature in tumors and
the degree of tumor differentiation. This finding is striking, since tumor differentiation/grade
is defined by histopathological criteria, and it was unclear whether the absence of well-
differentiated tissue traits would also entail a molecular similarity to an undifferentiated
stem cell state. Viewed from the perspective of global gene expression patterns, our results
indicate that this indeed may be the case.
We were struck by the association of the ES signature with high-grade tumors arising in
distinct tissues. In the breast and brain, this signature was detected in tumor subtypes
previously suggested to arise from oligopotent stem/progenitor cells37,47. Due to the
currently limited characterization of most normal adult stem cells, we were unable to assess
the similarity in gene expression profiles between such stem cells and ES cells. Moreover,
we cannot definitively determine whether the ES signature is inherited from a stem cell-of-
origin or, alternatively, is re-activated during the course of tumor progression.
Various parameters greatly affected our ability to associate gene-set enrichments with
specific tumor subtypes within expression datasets; these included the number of samples
profiled, tumor subtypes included, and clinical information available. The vast amount of
data collected for breast cancers allowed us to derive the most definitive conclusions
regarding this tumor type. Whether additional cancer types also possess the ES signature
must be determined in future studies.
Proliferative capacity and the ability to self-renew are integral aspects of adult and
embryonic stem cell identity. Distinct cell-cycle regulation mechanisms appear to control
the high proliferation rate and truncated G1 phase typical of ES cells39. Accordingly, it is
clear that genes associated with proliferation contribute to the ES signature described here
and to its detection in specific tumors. The separation of proliferation from stemness is
difficult, as exemplified by the dual roles of regulators such as Myc and β-catenin in both
proliferation and differentiation. However, our results indicate that the combined expression
patterns of the multiple genes within the analyzed gene sets reflect a complex ES-like
phenotype, which goes beyond a general state of proliferation. Moreover, our findings may
reflect a similarity in cell-cycle regulation between ES and cancer cells.
Breast cancer cells clearly differ from ES cells in multiple traits and do not possess their
pluripotent ability; we could not infer in detail from our gene sets which specific properties
are shared between ES and cancer cells. Among the activation targets of Nanog, Oct4 and
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Sox2, genes encoding transcription regulators were most consistently activated in high-grade
breast tumors. Importantly, in germ cell tumors, which are considered closer to ES cells and
often do express the NOS factors12,13,27, it is also the transcription factor-encoding NOS
targets that are preferentially overexpressed. These genes may therefore represent the core of
the regulatory network controlled by the NOS factors.
We identify a subgroup of transcription regulators that are highly (but not exclusively)
expressed in ES cells and that are preferentially expressed in high-grade tumors.
Interestingly, several of these genes are known to also function in adult stem/progenitor
cells. We suggest that the degree of tumor differentiation is determined, at least in part, by
the concerted activity of these factors, and in addition, that this activity contributes to
aggressive tumor behavior. Further functional studies will be necessary to determine the
roles of specific regulators in generating stem-like tumor phenotypes. In the longer term,
detailed characterization of the stem-cell regulatory networks active in cancer is likely to
yield powerful diagnostic and prognostic markers and, quite possibly, attractive targets for
therapeutic intervention.
Methods
Gene set compilation
Gene sets were collected directly from indicated publications (Table 1). We included all
genes for which we could convert the original gene identifiers into Entrez Gene IDs. Full
gene-set lists are in Supplementary Table 1. We constructed 3 gene sets of proliferation-
associated genes (Supplementary Table 3): the first including genes functionally associated
with cell-cycle progression and cell division according to Gene Ontology (GO) annotations;
the second, including cycling genes, was extracted from Whitfield et al.40; the third,
including the tumor-based Proliferation Cluster was extracted from Hu et al.35. Where
indicated, these genes were eliminated from our ES gene sets.
Expression data pre-processing
Expression data was imported from the referenced studies. Raw data was downloaded from
the NCBI GEO website or from websites indicated in the original publications, and
processed as described in Segal et al.18. Briefly, we first log2 transformed the expression
values, and then calculated the mean expression level for each gene across all samples in a
given dataset. These mean values were subtracted from all data points, such that expression
was represented relative to each gene’s mean, negative values representing below-mean
expression and vice versa. To construct the breast cancer compendium, we first normalized
each of the 6 included studies independently, and then concatenated these sets. The
compendium therefore does not represent a cross-comparison of expression levels between
samples from different studies, but, rather, the over- or underexpression of each gene within
the study in which it was performed. In cases where the same patients were included in more
than one of the 6 studies comprising the compendium, such redundancy was eliminated so
that each patient was included only once in the compendium. Specifically, patients of the
Uppsala cohort analyzed in the Miller30 set were eliminated from the Sotiriou29 and
Desmedt33 sets, and patients of the Oxford cohort present in the Sotiriou set were eliminated
from the Desmedt set. The normalized expression data files as well as sample annotations
can be found in http://jura.wi.mit.edu/bioc/benporath/.
Analysis of gene set enrichment patterns
To identify gene set enrichment patterns we used the methods described in Segal et al.18, as
embedded in the Genomica software (http://genomica.weizmann.ac.il/). For each sample
(array) we first scored the genes whose expression was at least 2-fold above or below the
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average expression level. We then assessed the fraction of over- or underexpressed genes
that belong to each tested gene set, calculating a P value according to the hypergeometric
distribution. This was repeated for every sample, using a threshold of P<0.05 for significant
enrichment. To compare enrichment patterns across sample groups we included clinical
annotations for each individual sample (e.g., grade, tumor size, ER status) derived from the
original publications. For all samples showing enrichment for a particular gene set, we
calculated the fraction of samples that possessed each annotation, and assigned a P-value
according to the hypergeometric distribution. We used a more stringent threshold, P<0.01,
for this calculation. In order to maintain consistent gene set enrichment significance results
independently of the number of sample annotations and of the number of gene sets tested,
we did not employ multiple hypothesis correction in these analyses. Heat maps showing
gene set enrichments in individual samples include only those samples enriched for at least
one set.
Classification of compendium samples to intrinsic subtypes
We employed the method published by Perou and colleagues to classify the 1,211 breast
cancer samples in the compendium to the five intrinsic subtypes35,48. This method uses 306
classifying genes whose level of expression in each of the 5 subtypes is represented in
centroids derived from a training set of breast cancers. A small number of the classifying
genes were included in some of our gene sets; elimination of these genes from our gene sets
did not substantially affect gene set enrichment patterns (data not shown).
Patient survival analysis
All patient survival data were extracted from the original publications. We defined
individual tumors as possessing an ES signature for this purpose if they were enriched for
both overexpression of the ES exp1 set and underexpression of the PRC2 targets set, and as
possessing a non-ES signature if they displayed the opposite enrichments. P values were
calculated using the log rank test and were calculated comparing the ES group to all other
patients. Meta-analysis of the overall survival of patients from the five studies indicated was
performed by combining the log hazard ratio estimated for each study, weighting by inverse
estimator variance according to the random effects procedure of DerSimonian and Laird49.
We eliminated patients of the Karolinska Institute cohort from the Desmedt33 patient set, to
avoid overlap with other sets. Analyses were performed using R package version 0.8-2
(http://cran.r-project.org), Guido Schwarzer (2007) meta: Meta-Analysis.
Analysis of transcription factor expression
We compiled a set of 68 transcription factors and specific chromatin modifiers included in
the NOS TFs, ES exp1 and ES exp2 gene sets (Supplementary Table 4). Hierarchical
clustering was performed on the expression values of these genes in the breast cancer
compendium data set using the R module pvclust50, with multiscale bootstrap resampling of
10,000 iterations to assess statistical significance, represented by a 1-100 score
(Supplementary Fig. 4b). Clustering was performed using the average agglomeration
method with correlation as the distance metric. This analysis identified a cluster of 9 genes
showing coordinated expression associated with poor breast tumor differentiation. We
searched for additional transcription regulators showing a similar expression pattern in the
breast cancer compendium by calculating the Pearson correlation coefficient of each of
1,700 transcription regulators in the human genome to the mean expression levels of the
original 9-gene cluster. Statistical significance was assessed as P<10-8 by reshuffling (106
iterations) of sample-gene associations.
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Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. An ES cell gene-set enrichment pattern
(a) Analysis method of gene set enrichment pattern18. For each sample (array) genes over-
and under- expressed relative to the mean across samples are scored. The fraction of these
differentially expressed genes that belong to each of the tested gene sets is then calculated,
and its significance over random is estimated, producing a P value. In the second step of the
analysis, the over-representation of particular sample groups among the samples enriched
for each gene set is assessed. (b) Gene set enrichments in ES cells compared to other cell
types. Columns represent individual samples (sample annotations on bottom), sample group
names are indicated above. Rows represent individual gene sets (names indicated on left).
Red – gene-set enrichment for overexpression, green - gene-set enrichment for
underexpression, black – no significant enrichment. (c) Enrichment pattern across sample
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groups. Numbers indicate P-values for gene set enrichment significance within sample
group, in negative log, e.g., 4 symbolizes P=10-4.
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Figure 2. Poorly differentiated breast cancers display an ES-like enrichment pattern
(a) Enrichment pattern of indicated gene sets (rows) across 1,211 breast cancer samples
included in 6 profiling studies (columns). Red/green – significantly over- or underexpressed
gene sets. Shown are 1,089 tumors for which both ER status and grade annotations were
available. Brown bars (bottom) indicate individual tumor annotations for grade, ER status,
and tumor size (T Sz), where available. S – tumor smaller than 2cm across (pathological
T1), L – tumor larger than 2cm (pathological T2 or T3). (b) Gene set enrichments in the
breast compendium tumors stratified by tumor grade.
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Figure 3. Association of the ES signature with ER status, tumor size, intrinsic subtype, and
prognostic outcome in breast cancers
(a) Gene set enrichments in the breast compendium tumors stratified by ER status, tumor
size (T Size) or intrinsic subtype. Stratification for the latter parameter was done by
employing an expression-profile based classification method35,48. S – small, L – large, Lum
– luminal. (b) Samples were divided into six groups representing different combinations of
tumor grade and ER-status, and enrichment of gene sets was tested across these groups
(left). A similar analysis was performed for grade and tumor size (right). (c) Enrichments in
tumors stratified by lymph-node metastasis absence (LN-) or presence (LN+), distant
metastasis (Met), or disease-induced mortality (Death). (d) Kaplan-Meier analyses of overall
survival in patients included in three of the five studies analyzed. Patients showing both
overexpression of the ES exp1 set and underexpression of the PRC2 targets set were labeled
as ES (red), those showing the reversed pattern were labeled as Non-ES (blue), and the
remainder were labeled as No signature (No sig, pink). P values indicate significance of
survival difference between the ES patient group and all other patients.
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Figure 4. Contribution of proliferation-associated genes to the ES signature
(a) Enrichment patterns in individual samples of ES cells and other cell types27 of the
indicated ES gene sets (as in Fig. 1), and of three Proliferation gene sets: Proliferation
Function - genes functionally associated with cell proliferation (compiled from several GO
categories), Cycling Genes – genes showing cell-cycle stage-specific expression40,
Proliferation Cluster – defined in tumor expression data35. Bar indicates difference in
enrichment pattern between ES gene sets and proliferation gene sets in cultured tumor cell
lines. (b) Gene set enrichment patterns across grade, ER-status and intrinsic subtypes after
subtraction of the Proliferation Function genes from all gene sets. Subtraction of the two
other proliferation sets is shown in Supplementary Fig. 2. (c) Enrichment pattern across
grade of different subsets of the ES exp1 gene set, based on their cellular function (GO).
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Figure 5. ES signature in high-grade glioblastomas and bladder carcinomas
(a) Gene set enrichment pattern across 157 normal brain and glioma samples41 of various
subtypes (bottom). Gene sets subtracted for proliferation genes are indicated as noprol. ODG
– oligodendroglioma, AC- astrocytoma, GBM – glioblastoma multiforme. (b) Gene set
enrichment pattern across normal bladder samples and grade 2 and 3 transitional cell
carcinomas (TCC)42. Invasive TCCs represent a tumor stage more advanced than superficial
tumors.
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Figure 6. A core set of ES-associated transcription factors is overexpressed in high-grade tumors
(a) Expression pattern of 59 genes encoding ES-associated transcription regulators (rows)
across the breast cancer compendium samples (columns), sorted by grade and ER status
(indicated in bottom). 12 additional genes in the ES TFs set were not represented in most of
the arrays used are therefore not shown. Red/green – two-fold or higher over- or
underexpression, respectively. White – missing data. (b) Core set of 9 closely correlated ES
transcription regulators, as determined by the pvclust method (Supplementary Figure 4b). (c)
Gene set enrichment in the breast cancer compendium samples of the 68 ES-associated
transcription regulators (ES TFs), the Core 9 gene subset (Core 9), and top ranking 100
genes in the nearest neighbor expression correlation analysis (NN top 100) – see panel f.
Shown are enrichments in individual tumors and in tumors stratified by grade, ER status and
intrinsic subtype. Only samples showing enrichment for at least one set are presented. (d)
Analysis as in C in glioma samples. NB – normal brain, other annotations as in Figure 5a.
(e) Analysis as in C in bladder carcinoma samples. NB – normal bladder, other annotations
as in Figure 5b. (f) 1,700 transcription regulators in the human genome were ranked
according to the similarity of their expression pattern in the breast cancer compendium to
the expression of the Core 9 gene cluster (nearest neighbor analysis). Shown are the top-
ranking 100 genes, in rank order (top down).
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